Package Leaflet: Information for the User
Ticagrelor Aristo 60 mg Film-Coated Tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
What is ticagrelor
Ticagrelor contains the active substance ticagrelor. It belongs to a group of medicines called antiplatelet agents.
What is ticagrelor used for
Ticagrelor, in combination with acetylsalicylic acid (another antiplatelet agent), should only be used in adults. You have been prescribed this medicine because you have had:
This medicine reduces the risk of you having another heart attack, a stroke, or dying from a heart or blood vessel-related disease.
How ticagrelor works
Ticagrelor works on cells called ‘platelets’ (also called thrombocytes). These very small blood cells help stop bleeding by clumping together to block small holes in blood vessels that are cut or damaged.
However, platelets can also form clots inside damaged blood vessels in the heart and brain. This can be very dangerous because:
Ticagrelor helps prevent platelets from clumping together. This reduces the chance of a blood clot forming that could reduce blood flow.
Do not take ticagrelor if:
Do not take ticagrelor if you are in any of the above situations. If you are unsure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before taking ticagrelor if:
If any of the above applies to you (or if you are unsure), consult your doctor or pharmacist before taking this medicine.
If you are taking ticagrelor and heparin:
Children and adolescents
Ticagrelor is not recommended for children and adolescents under 18 years of age.
Other medicines and ticagrelor
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. This is because ticagrelor may affect the way some medicines work and some medicines may affect ticagrelor.
Tell your doctor or pharmacist if you are taking any of the following medicines:
In particular, tell your doctor or pharmacist if you are taking any of the following medicines that increase the risk of bleeding:
Tell your doctor that, because you are taking ticagrelor, you may have a higher risk of bleeding if your doctor gives you fibrinolytics, often referred to as ‘clot dissolvers’, such as streptokinase or alteplase.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Ticagrelor is not recommended during pregnancy or if you can become pregnant. Women should use appropriate contraceptive methods to prevent pregnancy while taking this medicine.
Consult your doctor before taking this medicine if you are breastfeeding. Your doctor will explain the benefits and risks of taking ticagrelor during this time.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medicine.
Driving and using machines
Ticagrelor is unlikely to affect your ability to drive or use machines. If you feel dizzy or confused while taking this medicine, be careful while driving or using machines.
Ticagrelor Aristo contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose, which is essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you. If you are unsure, consult your doctor or pharmacist.
How much to take
Taking ticagrelor with other blood clotting medicines
Your doctor will also usually prescribe acetylsalicylic acid. This is a substance found in many medicines used to prevent blood clotting. Your doctor will tell you how much to take (usually between 75-150 mg daily).
How to take ticagrelor
You can take this medicine with or without food.
If you have difficulty swallowing the tablet
If you have difficulty swallowing the tablet, you can crush it and mix it with water as follows:
If you are in the hospital, this tablet may be given to you mixed with a little water through a tube in your nose (nasogastric tube).
If you take more ticagrelor than you should
If you take more ticagrelor than you should, talk to your doctor or go to the hospital immediately. Take the medicine pack with you. You may have a higher risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take ticagrelor
If you stop taking ticagrelor
Do not stop taking ticagrelor without consulting your doctor. Take this medicine regularly and for as long as your doctor tells you to. If you stop taking ticagrelor, you may increase the risk of having another heart attack or stroke, or dying from a heart or blood vessel-related disease.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may occur with ticagrelor:
Ticagrelor affects blood clotting, so most side effects are related to bleeding. Bleeding can occur anywhere in the body. Some level of bleeding is common (such as bruising and nosebleeds). Serious bleeding is rare but can be life-threatening.
Tell your doctor immediately if you notice any of the following - you may need urgent medical treatment:
Tell your doctor if you notice any of the following:
Other possible side effects
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Surveillance System for Human Use https://www.notificaRAM.es.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer packaging and on the blister after ‘EXP’. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Ticagrelo Aristo
The active ingredient is ticagrelor.
Each tablet contains 60 mg of ticagrelor.
The other components are:
Tablet core: mannitol (E421), calcium hydrogen phosphate dihydrate, sodium starch glycolate (Type A), hypromellose, and magnesium stearate.
Tablet coating: Opadry 03B240065 Pink: hypromellose, titanium dioxide, macrogol 400, red iron oxide (E172), and black iron oxide (E172).
Appearance of the Product and Package Contents
Round, biconvex, pink tablets, marked with '60' on one side and with an approximate diameter of 8 mm.
Available in PVC-PVDC/aluminum blister packs of 10 and 14 tablets.
Packs of 56, 60, and 168 tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Aristo Pharma GmbH
Wallenroder Straße 8-10
13435 Berlin, Germany
Manufacturer
KeVaRo GROUP Ltd.
9, Tsaritsa Eleonora Str.,
office 23,
Sofia 1618,
Bulgaria
Or
Adalvo Limited
Malta Life Sciences Park, Building 1, Level 4
Sir Temi Zammit Buildings
San Gwann Industrial Estate
San Gwann, SGN 3000
Malta
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
Aristo Pharma Iberia, S.L.
C/ Solana, 26
28850, Torrejón de Ardoz
Madrid, Spain
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Estonia Ticagrelor Aristo
Norway Ticagrelor Aristo 60 mg film-coated tablet
Germany Ticagrelor Aristo 60 mg film-coated tablets
Spain Ticagrelor Aristo 60 mg film-coated tablets EFG
Italy Ticagrelor Aristo 60 mg film-coated tablets
Portugal Ticagrelor Aristo
Poland Ticagrelor Aristo
Slovenia Ticagrelor Aristo 60 mg film-coated tablets
Date of the last revision of this leaflet:January 2022
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/